

• High and low glucose event detection rates

Indicator	True alert rate	False alert rate	Number of events	Correct detection rate	Missed detection rate	Number of events
Low glucose threshold, 70mg/dL	98.8%	1.2%	81	80.4%	19.6%	112
High glucose threshold, 200mg/dL	99.2%	0.8%	1543	85.9%	14.1%	347

iCan CGM system demonstrated reliable True alert rate (~99%) and Correct Detection rate warnings (>80%) across hyper- and hypoglycemic thresholds

Data on file, Sinocare
True alert: within 15 minutes before or after the low/high alert issued, there is reference measurement below/above the threshold level.
Correct detection: within 15 minutes before or after the reference measurement is below/above the threshold level, there is at least one low/high alert issued.

• No device related or severe adverse events reported
• No skin related adverse events reported

	iCan (n=60)				Type of adverse events (n=60)		
	No. of Events	No. of Patients	Rate (%)		No. of Events	No. of Patients	Incidence (%)
Total adverse events(AEs)	25	15	25.00%	Hyperglycemia	0	0	0.00%
Device related AEs	0	0	0.00%	Hypoglycemia	17	9	15.00%
Withdrawal due to AE	0	0	0.00%	Skin abnormality	0	0	0.00%
Severe AEs	0	0	0.00%	Others	8	7	11.67%
Device related severe AEs	0	0	0.00%	No skin abnormality adverse events reported			

Data on file, Sinocare
n, sample size; Ppt, people.

ClinicalTrials.gov study ID NCT05995756



CONTINUOUS GLUCOSE MONITORING SYSTEM



iCan is approved for patient use within Europe, U.K., PRC and India.

NPI031-MM-028


iCan CGM system has been clinically assessed in people with type 1 and type 2 diabetes as a self use home-care connected wearable.
Clinical data has been collected in China.

- High accuracy with single digit MARD / MAD across multiple different glucose ranges, including <70 mg/dL [<3.9 mmol/L]

YSI glucose level, mg/dL [mmol/L]	% within 15/15%	% within 20/20%	% within 30/30%	% within 40/40%	MAD, mg/dL or MARD,%	Matched pairs
<70 [<3.9]	94.74	100.00	100.00	100.00	9.93	39
70–180 [3.9–10.0]	83.64	93.00	98.69	99.56	8.94	1,143
181–250 [10.0–13.9]	85.38	93.99	98.96	100.00	7.99	383
>250 [>13.9]	92.23	97.09	99.03	100.00	6.14	103
Overall	84.83	93.65	98.80	99.70	8.71	1,668


Data on file, Sinocare
YSI, Yellow Springs Instrument; MAD, mean absolute difference is provided for glucose levels ≤70mg/dL;
MARD, mean absolute relative difference is provided for glucose levels >70mg/dL. Accuracy results for glucose values ≤70mg/dL are in mg/dL.

- iCan sensor stability provides a single digit MARD enduring over entire device 15 day wear life
- Overall MARD 8.71%



Data on file, Sinocare
CGM, continuous glucose monitoring; MARD, mean absolute relative difference


- Patients reported high comfort & convenience when attaching the iCan sensor on Day 1



Convenient sensor attachment

Good	Fair	Bad
94.74% (54)	5.26% (3)	0.00% (0)
91.23% (52)	8.77% (5)	0.00% (0)

- Patient reported feedback confirms convenience for 15 days



- Patient feedback shows high acceptance of the iCan App

High acceptance of iCan app

Good	Fair	Bad
92.98% (53)	5.26% (3)	1.76% (1)
91.23% (52)	7.02% (4)	1.75% (1)